Anderson KC - Search Results

1

Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.

Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP. Runnels JM, et al. Among authors: anderson kc. J Biomed Opt. 2011 Jan-Feb;16(1):011006. doi: 10.1117/1.3520571. J Biomed Opt. 2011. PMID: 21280893 Free PMC article.

2

NF-kappa B as a therapeutic target in multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. Hideshima T, et al. Among authors: anderson kc. J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872748 Free article.

3

Multiple myeloma.

Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446425 Review.

4

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

Hideshima T, Anderson KC. Hideshima T, et al. Among authors: anderson kc. Nat Rev Cancer. 2002 Dec;2(12):927-37. doi: 10.1038/nrc952. Nat Rev Cancer. 2002. PMID: 12459731 Review.

5

Apoptotic signaling in multiple myeloma: therapeutic implications.

Chauhan D, Hideshima T, Anderson KC. Chauhan D, et al. Among authors: anderson kc. Int J Hematol. 2003 Aug;78(2):114-20. doi: 10.1007/BF02983378. Int J Hematol. 2003. PMID: 12953804 Review.

6

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Mitsiades CS, et al. Among authors: anderson kc. Cancer Res. 2003 Oct 15;63(20):6689-96. Cancer Res. 2003. PMID: 14583463

7

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Mitsiades CS, et al. Among authors: anderson kc. Cancer Cell. 2004 Mar;5(3):221-30. doi: 10.1016/s1535-6108(04)00050-9. Cancer Cell. 2004. PMID: 15050914 Free article.

8

An update of novel therapeutic approaches for multiple myeloma.

Richardson P, Hideshima T, Anderson KC. Richardson P, et al. Among authors: anderson kc. Curr Treat Options Oncol. 2004 Jun;5(3):227-38. doi: 10.1007/s11864-004-0014-6. Curr Treat Options Oncol. 2004. PMID: 15115651 Review.

9

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.

Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. Podar K, et al. Among authors: anderson kc. Cancer Res. 2004 Oct 15;64(20):7500-6. doi: 10.1158/0008-5472.CAN-04-0124. Cancer Res. 2004. PMID: 15492276

10

Focus on multiple myeloma.

Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Mitsiades CS, et al. Among authors: anderson kc. Cancer Cell. 2004 Nov;6(5):439-44. doi: 10.1016/j.ccr.2004.10.020. Cancer Cell. 2004. PMID: 15542427 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,229 results

Search Page

Filters